Skip to main content

Advertisement

SpringerLink
Log in

Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Renal osteodystrophy is a major complication in hemodialysis patients. Measurement of serum peptide derived from the degradation of bone collagen could potentially provide an indirect estimate of bone resorption. The present study estimated the significance of the C-terminal telopeptide of type I collagen (β-CTx) as a serum bone resorption marker in male hemodialysis patients. The mean age and hemodialysis duration of the 160 patients were 59.7 years (26–86 years) and 67.2 months (17–142 months), respectively. Bone mineral density (BMD) in the distal third of the radius was measured using dual-energy X-ray absorptiometry twice with a 2-year interval. A blood sample was collected immediately before the hemodialysis session at the time of the second BMD measurement. Other serum bone markers determined were bone-specific alkaline phosphatase (BAP) and intact and N-terminal midfragment (N-Mid) osteocalcin (OC) as bone-formation markers and serum pyridinoline (PYD) and deoxypyridinoline (DPD) as bone resorption markers. Serum β-CTx correlated significantly in a positive manner with serum PYD, DPD, BAP, intact OC, and N-Mid OC. Serum β-CTx, as well as PYD, DPD, BAP, intact OC, and N-Mid OC, correlated significantly with BMD in the distal third of the radius at the second measurement and with the rate of BMD reduction during the preceding 2 years. The highest quartile of serum β-CTx was positively associated with rapid bone loss, defined as a change in the value for BMD in the distal third of the radius falling within the upper tertile of patients, in 55% of cases, and each quartile progress in serum β-CTx increased the odds ratio of rapid bone loss by a factor of 1.73. Since the Youden index was twice as accurate for β-CTx, BAP and N-Mid OC as for intact PTH, these bone-remodeling markers may be better risk markers of cortical bone loss than intact PTH. Inclusion in the highest quartile of PTH (above 288 pg/ml) predicted rapid bone loss with a sensitivity of only 26%. This means that the upper limit for serum PTH level recommended by K/DOQI may be too high, since 74% of cases with rapid bone loss showed serum PTH levels of below 288 pg/ml. In conclusion, serum measurement of β-CTx may provide a new commercially viable and relevant serum assay to reflect cortical bone resorption in hemodialysis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J (1988) Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30:57–62

    CAS  PubMed  Google Scholar 

  2. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11: S2–S17

    Article  PubMed  Google Scholar 

  3. Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M et al. (2001) Guidelines on the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 19:338–344

    Article  CAS  PubMed  Google Scholar 

  4. Furumitsu Y, Inaba M, Yukioka K, Yukioka M, Kumeda Y, Azuma Y et al. (2000) Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol 27:64–70

    CAS  PubMed  Google Scholar 

  5. Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y et al. (2002) Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 39:1261–1269

    Article  CAS  PubMed  Google Scholar 

  6. Ureña P, De Vemejoul MC (1999) Circulating biochemical markers of bone remodelling in uremic patients. Kidney Int 55:2141–2156

    Article  CAS  PubMed  Google Scholar 

  7. Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H et al. (2001) Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay that measures serum concentrations of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 47:1410–1414

    CAS  PubMed  Google Scholar 

  8. Fledelius C, Johnsen AH, Cloos PA, Bonde M, Quist P (1997) Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J Biol Chem 272:9755–9763

    Article  CAS  PubMed  Google Scholar 

  9. Bonde M, Qvist P, Fledelius C, Riis BJ, Chiristiansen C (1995) Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864–868

    Article  CAS  PubMed  Google Scholar 

  10. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Isikawa T, Morii H et al. (2000) Persistent increase in bone turnover in Graves’ patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157–4161

    Article  CAS  PubMed  Google Scholar 

  11. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T et al. (1999) Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int 9:525–531

    Article  CAS  PubMed  Google Scholar 

  12. Inaba M, Terada M, Nishizawa Y, Shioi A, Ishimura E, Otani S et al. (1999) Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Metabolism 48:904–909

    CAS  PubMed  Google Scholar 

  13. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C et al. (1998) A non-(1–94) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805–809

    CAS  PubMed  Google Scholar 

  14. Arnaud CD, Pun KK (1992) Metabolism and assay of parathyroid hormone. In: Coe FL, Favus MJ (eds) (1992) Disorders of bone and mineral metabolism. Raven Press, New York, pp 107–122

  15. Gomes B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff YD et al. (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560–1566

    CAS  PubMed  Google Scholar 

  16. Takahashi M, Kushida K, Nagano A, Inoue T (2000) Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 294:67–76

    Article  CAS  PubMed  Google Scholar 

  17. Rosenquist C, Qvist P, Bjarnason N, Christiansen C (1995) Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439–1445

    CAS  PubMed  Google Scholar 

  18. Niwa T, Shiobara K, Hamada T, Miyazaki T, Tsukushi S, Uema K et al. (1995) Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta 235:33–40

    Article  CAS  PubMed  Google Scholar 

  19. Pagani F, Bonetti G, Stefini F, Panteghini M (2000) Evaluation of a fully automated assay to measure C-telopeptide of type I collagen in serum. Clin Chem Lab Med 38:1111–1113

    CAS  PubMed  Google Scholar 

  20. Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S (1996) Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 19:549–555

    Article  CAS  PubMed  Google Scholar 

  21. Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ (1996) Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 28:515–522

    CAS  PubMed  Google Scholar 

  22. Miki T, Morita A, Nakatsuka K, Tabata T, Inoue T, Nishizawa Y et al. (1997) Changes in bone mineral density in patients on hemodialysis due to chronic glomerulonephritis. Osteoporos Int 7:S193–S196

    PubMed  Google Scholar 

  23. Lindergard B, Cederholm B (1994) Long-time follow-up (10–22 years) of bone mineral density in patients on uninterrupted hemodialysis for more than 10 years. Bone Miner 25:S38

    Google Scholar 

  24. Rosen HM, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL et al. (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100–103

    CAS  PubMed  Google Scholar 

  25. Malyszko J, Wolczynski S, Zbroch E, Brzosko S, Malyszko J, Mysliwiec M (2001) Serum crosslaps correlations with serum ICTP and urine DPD in hemodialyzed and peritoneally dialyzed patients. Nephron 87:283–285

    Article  CAS  PubMed  Google Scholar 

  26. National Kidney Foundation (2003) K/DOQI clinical practice guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–S202

    Google Scholar 

  27. Ureña P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS et al. (1995) Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 10:932–939

    CAS  PubMed  Google Scholar 

  28. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD (1999) Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 14:1614–1621

    CAS  PubMed  Google Scholar 

  29. Ross PD, Knowlton W (1998) Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 13:297–302

    CAS  PubMed  Google Scholar 

  30. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL (1996) Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 59:328–333

    Article  CAS  PubMed  Google Scholar 

  31. Parfitt AM (1998) A structural approach to renal bone disease. J Bone Miner Res 13:1213–1220

    CAS  PubMed  Google Scholar 

  32. Schober HC, Han ZH, Foldes AJ, Shih MS, Rao DS, Balena R et al. (1998) Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 9:1225–1233

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shirasagi Hospital, 7-11-23 Kumata, Higashisumiyoshi-ku, 546-0002, Osaka, Japan

    Senji Okuno, Kayoko Kitatani & Tomoyuki Yamakawa

  2. Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 1-4-3, Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan

    Masaaki Inaba, Eiji Ishimura & Yoshiki Nishizawa

Authors
  1. Senji Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaaki Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kayoko Kitatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eiji Ishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoyuki Yamakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshiki Nishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaaki Inaba.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okuno, S., Inaba, M., Kitatani, K. et al. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16, 501–509 (2005). https://doi.org/10.1007/s00198-004-1712-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-004-1712-4

Keywords

Search

Navigation